Valerie Liesbeth Brigitte Vanhooren

Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona.

Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain.

Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain.

Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain.

iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

Hunza Management SARL is a private equity firm headquartered in Luxembourg. The current firm was established in 1998 to manage Hunza Ventures, the venture capital investment vehicle of the family of the retired Belgian entrepreneur Guy Ullens. Baron Guy Ullens de Schooten and the Wittouck family built up and controlled the diversified European food manufacturing group Artal, based in Luxembourg and historically focused on the Belgian sugar industry.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium.

FORMAC Pharmaceuticals NV engages in drug delivery and development services. The firm applies its silica based drug delivery platforms for improving in vivo performance of poorly soluble compounds. The company was founded by Johan A. Martens, Paul Joseph Rutgeerts, Guy Van den Mooter and Jan Baptist Van Humbeeck in 2007 and is headquartered in Heverlee, Belgium.

DeepUll Diagnostics SL provides technical engineering and consulting services. The company is based in Barcelona, Spain. The Spanish company was founded in 2019 by Jordi Carrera Fabra and Rafel Bru. Jordi Carrera Fabra has been the CEO since 2019.

Columbus Venture Partners SGEIC SA (Columbus VP) is an independent Spanish venture capital firm which was founded in 2015 by Javier García Cogorro and Damià Tormo Carulla. The firm headquartered in Madri, Spain.

Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain.

Exact Imaging, Inc. provides high resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Its ExactVu micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and being an extension of the current urological workflow. The company was founded by Sam Ifergan and Randy AuCoin in 2013 and is headquartered in Markham, Canada.

Accure Therapeutics SL is an R & D pharma Spanish company that focuses on developing innovative medicines to treat patients suffering from central nervous system diseases. Accure Therapeutics is based in Barcelona, ES, and has subsidiaries in Spain. The company's research is centered on neurons that suffer dysfunction and the glial environment that supports them, with the aim of impeding their degeneration and death. The company was founded in 2020 by Laurent Nguyen, who has been the CEO since then.

Altamar Private Equity SGIIC SA (Altamar Private Equity) is a private equity arm of Altamar Capital Partners SL founded in 2004. The firm is headquartered in Spain with additional offices in New York and Santiago de Chile.

Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain.

MTrap, Inc. engages in the development of novel therapeutic devices that interfere with the intense dialogue and crosstalk between the primary tumor and the microenvironment and represent a new disruptive approach to cancer treatment. The company was founded by Maybelle L. Jordan and is headquartered in Huntington, NY.

STAT-Dx Life SL focuses on the development, manufacturing and commercialization of diagnostic solutions for fast and accurate diagnostic results of infectious diseases and critical care. It solution offers DiagCORE Cartridge, for sample and analyzation of cell material, nucleic acid purification, amplification and hybridization process. The company was founded by Jordi Cabrrera Fabra and Rafael Bru Gibert in 2010 and is headquartered in Barcelona, Spain.

EPICS Therapeutics SA engages in the development of therapeutic solutions for cancer. The company was founded by Jean Combalbert, Alain Parthoens and Francois Fuks on February 20, 2018 and is headquartered in Charleroi, Belgium.

FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.

Tissium SA engages in the development and commercialization of biodegradable sealants and adhesives for invasive surgery. It offers biomimetic wound closure solutions. The company was founded by Bernard J. Gilly, Robert S. Langer, Christophe Bancel, Jeff Karp, Jacques Marescaux, Maria Pereira, and Patrick Houvet in 2013 and is headquartered in Paris, France.

GMP-Orphan SA engages in the research and development in biotechnology. It focuses on developing and designing drugs for life-threatening and rare diseases. The company was founded by Frederic Marin on July 18, 2011 and is headquartered in Paris, France.

Mazars Group provides audit, accountancy, tax, legal, and advisory services. Its services include financial reporting audit and advisory, consulting, financial advisory, outsourcing and accounting, actuarial, and international desks services. The company was founded by Robert Mazars in 1940 and is headquartered in Montr?al, Canada.

CDC Enterprises, Inc. designs, manufactures, and distributes patented HDPE ductwork products. It offers airtight, mildew, corrosion resistant, and thermal constructed ductwork products. The firm specializes in electrical instrumentation, controls and systems integration, for public works, utilities, private industry, and government organizations. It provides a wide range of services including pump efficiency monitoring, system diagnostics and troubleshooting, GPS mapping, robotic controls, panel design, and fabrication. The company was founded by Jon W. Jungers in April 2001 and is headquartered in Ringwood, IL.

Iteos Belgium SA manufactures pharmaceutical raw materials. The private company is based in Gosselies, Belgium.

Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium.

Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Sagetis Biotech SL designs and develops drug-delivery technologies. Its polymeric-based platforms are designed to address areas such as" delivery through the blood-brain barrier, genetic material transfection, and tissue regeneration. The company was founded by David Horna, Eduard Diviu Terradas and Salvador Borros Gomez on April 14, 2010, and is headquartered in Barcelona, Spain.

ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021.

National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD.